Francis Fagnani

Summary

Affiliation: Cemka Eval
Country: France

Publications

  1. ncbi Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma
    A Lafuma
    CEMKA, 43 boulevard du maréchal Joffre, F 92340, Bourg la Reine, France
    Eur J Cancer 37:369-75. 2001
  2. doi [Use of drug reimbursement as markers of disease for epidemiological and cost analysis: The case of severe epilepsy in France]
    Francis Fagnani
    Cemka Eval, 43, boulevard du Maréchal Joffre, 92340 Bourg la Reine, France Electronic address
    Presse Med 42:e285-92. 2013
  3. doi [The investment of pharmaceutical industry in hospital clinical research: an estimate for france in 2010]
    Francis Fagnani
    Cemka Eval, 43 boulevard du maréchal Joffre, 92340 Bourg la Reine, France
    Therapie 67:89-96. 2012
  4. pmc Prevalence of visual impairment in relation to the number of ophthalmologists in a given area: a nationwide approach
    Antoine J Lafuma
    Health Qual Life Outcomes 4:34. 2006
  5. pmc Prevalence and burden of self-reported blindness and low vision for individuals living in institutions: a nationwide survey
    Antoine Pierre Brézin
    Hopital Cochin, Service d Ophtalmologie, Universite Paris 5, 27 rue du Faubourg Saint Jacques, F 75679 Paris cedex 14, France
    Health Qual Life Outcomes 3:27. 2005
  6. pmc Prevalence of mental disorders in French prisons for men
    Bruno Falissard
    INSERM U669, Maison de Solenn, 97 Bd du Port Royal, 75679 Paris, France
    BMC Psychiatry 6:33. 2006
  7. ncbi Antibiotic prescribing patterns of French GPs for upper respiratory tract infections: impact of fusafungine on rates of prescription of systemic antibiotics
    Francis Fagnani
    Cemka Eval, Bourg la Reine, France
    Am J Respir Med 2:491-8. 2003
  8. ncbi [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer]
    Francis Fagnani
    Cemka Eval, 43, boulevard du Maréchal Joffre, 92340 Bourg la Reine
    Bull Cancer 94:711-20. 2007
  9. ncbi Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications
    F Fagnani
    CEMKA, Bourg la Reine, France
    Dement Geriatr Cogn Disord 17:5-13. 2004
  10. ncbi Management of hypertension and screening of renal complications by GPs in diabetic type 2 patients (France--2001)
    F Fagnani
    CEMKA, Bourg la Reine, France
    Diabetes Metab 29:58-64. 2003

Detail Information

Publications37

  1. ncbi Economic analysis of adjuvant therapy with interferon alpha-2a in stage II malignant melanoma
    A Lafuma
    CEMKA, 43 boulevard du maréchal Joffre, F 92340, Bourg la Reine, France
    Eur J Cancer 37:369-75. 2001
    ..Assuming that there is an improvement in disease-free survival only, cost is 26147 per Q-TWIST. Cost-effectiveness of IFNalpha-2a in stage II melanoma compares favourably with estimates for widely used therapies in the oncological field...
  2. doi [Use of drug reimbursement as markers of disease for epidemiological and cost analysis: The case of severe epilepsy in France]
    Francis Fagnani
    Cemka Eval, 43, boulevard du Maréchal Joffre, 92340 Bourg la Reine, France Electronic address
    Presse Med 42:e285-92. 2013
    ..This study explored the possibility to use the French Sickness Fund (FSF) database to determine the prevalence and direct cost of epilepsy...
  3. doi [The investment of pharmaceutical industry in hospital clinical research: an estimate for france in 2010]
    Francis Fagnani
    Cemka Eval, 43 boulevard du maréchal Joffre, 92340 Bourg la Reine, France
    Therapie 67:89-96. 2012
    ..6 M€ of medical honoraria (17%), 73 M€ of hospital extra cost (15%), 99 M€ of drug provision (20%) and 232 M€ of internal cost for french affiliates (48%)...
  4. pmc Prevalence of visual impairment in relation to the number of ophthalmologists in a given area: a nationwide approach
    Antoine J Lafuma
    Health Qual Life Outcomes 4:34. 2006
    ..Sociological and economic risk factors of visual impairment have never been described in France at a national level as the association between the number of ophthalmologists per inhabitant and visual impairment prevalence...
  5. pmc Prevalence and burden of self-reported blindness and low vision for individuals living in institutions: a nationwide survey
    Antoine Pierre Brézin
    Hopital Cochin, Service d Ophtalmologie, Universite Paris 5, 27 rue du Faubourg Saint Jacques, F 75679 Paris cedex 14, France
    Health Qual Life Outcomes 3:27. 2005
    ..The prevalence of self-reported low vision (LV) and blindness, and their associated disabilities, handicaps and socio-economic consequences for individuals living in institutions are poorly documented...
  6. pmc Prevalence of mental disorders in French prisons for men
    Bruno Falissard
    INSERM U669, Maison de Solenn, 97 Bd du Port Royal, 75679 Paris, France
    BMC Psychiatry 6:33. 2006
    ..Psychiatric surveys conducted in prison populations find high prevalence rates, but diagnoses may be difficult in this particular context. None of these surveys have been conducted in France...
  7. ncbi Antibiotic prescribing patterns of French GPs for upper respiratory tract infections: impact of fusafungine on rates of prescription of systemic antibiotics
    Francis Fagnani
    Cemka Eval, Bourg la Reine, France
    Am J Respir Med 2:491-8. 2003
    ..Drug costs to the French National Sickness Fund were also assessed...
  8. ncbi [Cost/effectiveness analysis of adjuvant therapy with trastuzumab in patients with HER2 positive early breast cancer]
    Francis Fagnani
    Cemka Eval, 43, boulevard du Maréchal Joffre, 92340 Bourg la Reine
    Bull Cancer 94:711-20. 2007
    ....
  9. ncbi Donepezil for the treatment of mild to moderate Alzheimer's disease in France: the economic implications
    F Fagnani
    CEMKA, Bourg la Reine, France
    Dement Geriatr Cogn Disord 17:5-13. 2004
    ..Overall, these data suggest that donepezil is a cost-effective treatment for mild to moderately impaired AD patients living in France...
  10. ncbi Management of hypertension and screening of renal complications by GPs in diabetic type 2 patients (France--2001)
    F Fagnani
    CEMKA, Bourg la Reine, France
    Diabetes Metab 29:58-64. 2003
    ..Our aim was to assess the quality of the medical management by GPs of hypertension and renal insufficiency in type 2 diabetic patients...
  11. ncbi Economic evaluation of a combined DTPa, hepatitis B, polio, Hib vaccine. Potential impact of the introduction of Infanrix-Hexa in the French childhood immunisation schedule
    Francis Fagnani
    CEMKA, 43 boulevard Maréchal Joffre, 92340 Bourg la Reine, France
    Eur J Health Econ 5:143-9. 2004
    ..20 euro per child, or about 21 million euro for an annual cohort of 760,000 births (total cost, 35 million euro). The number of infants protected against hepatitis B could increase from 230,000 in the current situation to about 600,000...
  12. ncbi [Cost of obesity in France]
    Corinne Emery
    Cemka Eval, Bourg la Reine
    Presse Med 36:832-40. 2007
    ..To estimate the costs associated with obesity in France...
  13. doi [Budget impact analysis of Pradaxa thromboprophylaxis after total hip or total knee replacement]
    Stéphane Bouée
    Cemka Eval, Bourg la Reine, France
    Therapie 64:249-57. 2009
    ..A univariate sensitivity analysis showed that the budget impact was robust and remained positive with the utilisation of Pradaxa in all cases tested...
  14. ncbi Seroprevalence of varicella in the French population
    Babak Khoshnood
    Cemka Eval, Bourg la Reine, France
    Pediatr Infect Dis J 25:41-4. 2006
    ..To assess the age-specific seroprevalence of varicella in the French population and to explore age-adjusted differences according to gender and geographic region...
  15. ncbi [ENVOL study on the medical management of varicella and its complications in French ambulatory care]
    C Emery
    Cemka Eval, 43, boulevard du Maréchal Joffre, 92340 Bourg la Reine, France
    Med Mal Infect 36:92-8. 2006
    ..The authors had for aim to describe the management of varicella and its complications in French ambulatory care...
  16. ncbi Estimation of direct unit costs associated with non-vertebral osteoporotic fractures in five European countries
    S Bouee
    CEMKA, 43 boulevard du maréchal Joffre, 92340 Bourg la Reine, France
    Rheumatol Int 26:1063-72. 2006
    ..The costs of those fractures should be considered when estimating the cost of osteoporosis...
  17. ncbi Economic evaluation of enoxaparin sodium versus heparin in unstable angina. A French sub-study of the ESSENCE trial
    B Detournay
    Health Economics Department, CEMKA, Bourg la Reine, France
    Pharmacoeconomics 18:83-9. 2000
    ..To perform an evaluation from the societal perspective of the cost of treatment with enoxaparin sodium versus unfractionated heparin (UFH) in patients with unstable angina and non-Q wave myocardial infarction in France...
  18. ncbi [Medical resources consumption of type 2 diabetics in France in 1998]
    B Detournay
    CEMKA, 43 boulevard du maréchal Joffre, 92340 Bourg la Reine France
    Diabetes Metab 26:225-31. 2000
    ..CODE-2 study reveals the high level of medical resources consumption associated with type 2 diabetes complication. It confirms that more efficient therapeutical strategies are needed to avoid these complications...
  19. ncbi [Epidemiology, management and costs of type 2 diabetes in France in 1998]
    B Detournay
    CEMKA, Bourg la Reine
    Diabetes Metab 25:356-65. 1999
    ..As diabetes has become a national public health priority, it is important to initiate new studies to have precise indicators in these different fields...
  20. ncbi Managing type 2 diabetes in France: the ECODIA survey
    B Detournay
    CEMKA, 43 boulevard Maréchal Joffre, F 92340 Bourg la Reine, France
    Diabetes Metab 26:363-9. 2000
    ..This survey confirms that the management of patients with type 2 diabetes is still often inappropriate in France despite recent progress. Improved disease management and monitoring is required in France as in other developed countries...
  21. ncbi Obesity morbidity and health care costs in France: an analysis of the 1991-1992 Medical Care Household Survey
    B Detournay
    CEMKA, 43 boulevard Maréchal Joffre, 92340 Bourg la Reine, France
    Int J Obes Relat Metab Disord 24:151-5. 2000
    ..To estimate the direct medical costs associated with obesity in France...
  22. ncbi Irritable bowel syndrome in France: quality of life, medical management, and costs: the Encoli study
    Catherine Brun-Strang
    Novartis Pharma, Rueil Malmaison, Bourg la Reine, France
    Eur J Gastroenterol Hepatol 19:1097-103. 2007
    ..To assess the proportion of physician-diagnosed irritable bowel syndrome (IBS) patients who conform to Rome II criteria, and evaluate the impact of IBS on quality of life (QoL) and costs in France...
  23. ncbi Changes in osteoarthritis management by general practitioners in the COX2-inhibitor era-concomitant gastroprotective therapy
    Stéphane Bouée
    Cemka Eval, 43, boulevard du Maréchal Joffre, 92340 Bourg la Reine, France
    Joint Bone Spine 71:214-20. 2004
    ..We evaluated their use in the treatment of osteoarthritis by general practitioners, with special attention to concomitant prescription of gastroprotective agents...
  24. ncbi Nonmedical economic consequences attributable to visual impairment: a nation-wide approach in France
    Antoine Lafuma
    Cemka Eval, Bourg la Reine, France
    Eur J Health Econ 7:158-64. 2006
    ..Resource allocation strategies aimed at controlling visual impairment should cover all relevant economic dimensions, including nonmedical items...
  25. ncbi [Bipolar I disorder in France: prevalence of manic episodes and hospitalisation-related costs]
    M De Zelicourt
    Cemka Eval, 43, boulevard du Maréchal Joffre, 92340 Bourg la Reine
    Encephale 29:248-53. 2003
    ....
  26. ncbi [The EPO beta injection pen in patients in maintenance dialysis or predialysis: acceptability, satisfaction and cost assessment]
    Corinne Emery
    Cemka Eval, Bourg la Reine
    Presse Med 32:1907-12. 2003
    ..This study was aimed at evaluating the acceptability and economic impact of the utilisation of Reco-Pen, an injection pen equipped with cartridges in patients requiring treatment with recombinant human erythropoietin (rHu-EPO)...
  27. ncbi Frequency of hospitalisations and inpatient care costs of manic episodes: in patients with bipolar I disorder in France
    Marie de Zelicourt
    Cemka Eval, 43 Boulevard de maréchal Joffre, 92340, Bourg la Reine, France
    Pharmacoeconomics 21:1081-90. 2003
    ..Bipolar disorder is a chronic illness that may involve multiple relapses and result in substantial psychosocial impairment. However, very few recent studies have investigated the economic burden of the disease...
  28. ncbi Cost effectiveness of a low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement
    B Detournay
    CEMKA, Bourg la Reine, France
    Pharmacoeconomics 13:81-9. 1998
    ..Such prophylaxis also appears to be clearly cost effective, using French cost data...
  29. doi [Projection of the incidence of breast cancer in France in 2018]
    S Bouee
    CEMKA, 43, boulevard du Maréchal Joffre, 92340 Bourg la Reine, France
    Bull Cancer 97:293-9. 2010
    ..This factor alone explains 18% of the growth in the number of incident cases in 2018, while the effect of population growth account for 6.6%, the cessation of HTM a 6.4% decrease and aging a 4.6% growth...
  30. ncbi An economic evaluation of tiludronic acid treatment in Paget's disease of bone
    A Lafuma
    CEMKA, Bourg la Reine, France
    Pharmacoeconomics 12:460-74. 1997
    ....
  31. ncbi [Breast cancer screening in France]
    Thierry Philip
    Centre Léon B6rard Gresac, UMR 58 23, 28 rue Laennec, 69373 Lyon
    Bull Acad Natl Med 189:321-36; discussion 336-9. 2005
    ..After analysing the outcome of screening, particularly the results of the 2003 Cancer Plan, the authors considered the risks of screening, and the type of information given to women...
  32. ncbi Prevalence and burden of self-reported blindness, low vision, and visual impairment in the French community: a nationwide survey
    Antoine Pierre Brézin
    Service d Ophtalmologie, Universite Paris Descartes, Faculte de Medicine, Hopital Cochin, Universite Paris 5, 27 rue du Faubourg Saint Jacques, 75679 Paris Cedex 14, France
    Arch Ophthalmol 123:1117-24. 2005
    ..To estimate the prevalence of self-reported visual impairment and its association with disabilities, handicaps, and socioeconomic consequences...
  33. doi [General practitioners' management of gastroesophageal reflux in France in 2005: a pharmacoeconomic study]
    Stephane Mouly
    Assistance Publique Hopitaux de Paris, Unité de recherches thérapeutiques, Service de Medecine Interne A, Hopital Lariboisiere, F 75010 Paris, France
    Presse Med 37:1397-406. 2008
    ..e., 5.7% of community pharmaceutical expenditures, 50% prescribed for gastroesophageal reflux disease (GERD))...
  34. ncbi Performance of a new, liquid-based cervical screening technique in the clinical setting of a large French laboratory
    Christine Bergeron
    Laboratoire Pasteur Cerba, 95066 Cergy Pontoise, France
    Acta Cytol 47:753-61. 2003
    ....
  35. ncbi Patients with Alzheimer's disease living at home in France: costs and consequences of the disease
    Anne Sophie Rigaud
    Hopital Broca, Paris, France
    J Geriatr Psychiatry Neurol 16:140-5. 2003
    ..This study suggested a significant link between costs of caring for an AD patient at home and disease severity...
  36. ncbi [Methodology and quality control in EPIGRAM, a pharmacoepidemiological study of obesity in general practice]
    Muriel Vray
    Unité d Epidémiologie des Maladies Emergentes, Institut Pasteur, Bâtiment Laveran, Paris, France
    Therapie 59:573-9. 2004
    ..Of the patients treated with orlistat on inclusion, 17% were lost to follow-up by their GP and 25% were contacted directly at the end of the study...
  37. ncbi [Results from the observational study EPIGRAM: management of excess weight in general practice and follow-up of patients treated with orlistat]
    Muriel Vray
    Institut Pasteur, Bâtiment Laveran, Paris, France
    Therapie 60:17-24. 2005
    ..The treatment cost was the main reason for definitive treatment discontinuation for more than 50% of the patients. The average weight loss was 5% and 9% after 3 and 12 months of treatment, respectively...